Navigation Links
Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Date:6/2/2008

ing the clinical safety endpoints. There were no observed clinically relevant adverse events associated with the treatment at all the concentrations (0 to 40 mg of SL017) and light doses (10 to 20 joules/cm(2)) administered. The light treatment, conveniently administered in a dermatology clinic, was well tolerated. The therapeutic potential of SL017 was evidenced by the expected (PDT) effects, such as redness, edema, occasional blisters, stinging and burning. The clinical correlates of dyskeratosis and inflammation were likewise appropriately noted on skin biopsy. Clinical and pathological results correlated very well, and conformed not only to the expected effects of PDT but also to the dosage of the drug and light energy administered. The study suggests that a 2% topical formulation of SL017 and a fluence of 20 joules/cm (2) provide expected PDT outcomes. Importantly, this Phase I study did not identify any safety concerns with respect to the parameters evaluated at the dosages of drug and light employed.

"I am encouraged by the confirmation of the topical PDT effects of SL017 and its potential for future applications in a variety of dermatological conditions including Actinic Keratosis," commented Dr. Gilles Lauzon, former Director, Division of Dermatology, University of Alberta and one of the investigators of the study.

The potential applications of cutaneous PDT also include acne, rosacea, superficial skin cancers, cutaneous T-cell lymphoma, localized scleroderma, warts, leishmaniasis and skin rejuvenation. Quest has already shown the follicular uptake of SL017 in humans; and is currently conducting a 90-patient trial addressing potential hair removal applications with results anticipated by end of this year. The Company is also evaluating the utility of SL017 for the treatment of acne in a preclinical model.

Paramount Biosciences, a global pharmaceutical and healthcare investment firm, has exclusive rights to develop and commercialize SL01
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... CA (PRWEB) April 23, 2015 Athena ... personal development of executive women in San Diego’s technology ... the 17th Annual Pinnacle Awards at their Gala on ... Hyatt Hotel. Register now at http://athenasd.org/events/ , ... support the Athena San Diego vision of fostering networking, ...
(Date:4/23/2015)... April 23, 2015 Six startups ... on April 4-17 as part of the U.S.-Russia ... fourth group of biotechnology startups to participate in ... Novgorod (UNN) and the University of Maryland (UMD) ... between their respective universities in the biomedical industry ...
(Date:4/23/2015)... , April 23, 2015  Cryoport, Inc. ... cryogenic logistics solutions for the life sciences industry, ... its cryogenic logistics solutions within the animal husbandry ... Yancey Farms to support the shipment of equine ... Sport horse Stallions. Animal husbandry ...
(Date:4/23/2015)... CA (PRWEB) April 23, 2015 ... leader in Personalized Medicine, is excited to announce ... Response profile . This profile assesses 62 genetic ... provide dosing information for commonly prescribed non-opioid pain ... (brand name Neurontin), alprazolam (brand name Xanax) and ...
Breaking Biology Technology:Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 3Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3
... (Nasdaq: NLTX ), announced today that Peter Strumph, ... Investor Forum on Thursday,October 30th, at 9:00 a.m. PT ... Strumph will provide an overview of Nile and an ... Nile,s Phase 2a,study for its lead compound, CD-NP, a ...
... be tested in AMD patients, LOUISVILLE, Ky., ... company developing medicines for the treatment,of age-related macular ... presenting its ASaP Phase I clinical data for ... Day at the American,Academy of Ophthalmology (AAO) Annual ...
... to Launch First Lower-Dose, Extended-Cycle Oral Contraceptive,for ... Oct. 27 Barr Pharmaceuticals,Inc. (NYSE: ... Food and Drug Administration,(FDA) has approved its ... for LoSEASONIQUE(R) (levonorgestrel/ethinyl estradiol,tablets 0.10 mg/0.02 mg ...
Cached Biology Technology:Nile Therapeutics to Present at the 7th Annual BIO Investor Forum 2Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting 2Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting 3FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 2FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 3FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 4FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 5
(Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... and Voice Biometrics - Global Strategic Business Report" report to ... Face and Voice Biometrics in US$ Thousands by the following Segments: ... for the US, Canada , Japan ... , Middle East & Africa ...
(Date:3/23/2015)... LOS ANGELES , March 23, 2015  In ... in Federal fraud case conviction losses. This figure accounts ... fraud, which, according to The Nilson Report, exceeds $11 ... an investigative tool after a crime has occurred. Investor ... Agent and polygraph expert Joe Paolella partnered ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... Technology , published by Wiley-Blackwell, spotlights recent developments ... athletes and para-athletes, with two published articles highlighting ... of double transtibial amputee sprinting using dedicated sprinting ... mechanics data of able-bodied sprinters with that of ...
... up the dangerous contaminants dry-cleaning fluids, solvents and ... of the most urgent challenges facing environmental science. A ... (EPA) sheds light on a new way to monitor ... technique developed at the University of Toronto. "The ...
... than 200 scientists from around the world have ... ESRIN, ESA,s Earth Observation centre in Frascati, Italy. ... providing vital information on our planet that could ... wetland preservation and improve climate models. Using ...
Cached Biology News:U of T technique put to use to test clean up of contaminated groundwater 2New satellite techniques for looking at climate change 2New satellite techniques for looking at climate change 3
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Apoptosis Detection Systems and Reagents...
Apoptosis Detection Systems and Reagents...
... These plastic feeding tubes for rodent oral ... the risk of perforation and trauma. Plus ... of cleaning and the risk of cross-contamination. ... 20ga Length: ...
Biology Products: